Swedish Orphan Biovitrum AB/Skr SOBI
07:00
09:05
11:15
13:20
15:25
1D1W1MYTD1Y5YMAX
About Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB is a biotechnology company primarily focused on developing and commercializing specialty pharmaceuticals for rare diseases. The company is active in therapeutics for hematology, immunology, and genetic and metabolic disorders. Swedish Orphan Biovitrum was founded in 2001 and is headquartered in Stockholm, Sweden. The company operates globally, reaching markets in Europe, North America, and other regions. A key aspect of its strategic positioning is its commitment to addressing unmet medical needs in rare diseases, which often provides a unique market niche. The company invests significantly in research and development to fuel growth and innovation in its therapeutic areas.
Ticker
Skr SOBI
Sector
Primary listing
XSTO
Employees
2,119
Headquarters
Stockholm, Sweden
Website
SOBI Metrics
BasicAdvanced
kr 164bn
119.88
kr 3.96
0.29
-
Price and volume
Market cap
kr 164bn
Beta
0.29
52-week high
kr 487.00
52-week low
kr 261.20
Average daily volume
467k
Financial strength
Current ratio
0.875
Quick ratio
0.551
Long term debt to equity
20.663
Total debt to equity
41.607
Interest coverage (TTM)
13.34%
Profitability
EBITDA (TTM)
12,414
Gross margin (TTM)
78.49%
Net profit margin (TTM)
4.51%
Operating margin (TTM)
30.53%
Effective tax rate (TTM)
-11.71%
Revenue per employee (TTM)
kr 14,450,000
Management effectiveness
Return on assets (TTM)
7.71%
Return on equity (TTM)
3.40%
Valuation
Price to earnings (TTM)
119.879
Price to revenue (TTM)
5.35
Price to book
3.89
Price to tangible book (TTM)
-8.63
Price to free cash flow (TTM)
36.047
Free cash flow yield (TTM)
2.77%
Free cash flow per share (TTM)
13.155
Growth
Revenue change (TTM)
13.54%
Earnings per share change (TTM)
-68.61%
3-year revenue growth (CAGR)
15.07%
10-year revenue growth (CAGR)
21.58%
3-year earnings per share growth (CAGR)
-27.09%
10-year earnings per share growth (CAGR)
6.15%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.